The company is targeting its RPPA-based testing to biopharma firms as well as for clinical trial work and to clinicians to help guide therapy in cancer patients.

Here the authors identify that a microprotein HDSP derived from the long non-coding RNA HOXA10-HOXA9 is overexpressed in gastric cancer and forms a positive feedback loop with MECOM to drive EGFR ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment ...

Researchers from the University of Alabama at Birmingham have identified a promising new combination therapy for metastatic colorectal cancer that enhances the effectiveness of existing treatment ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

Pacylex was recognized as BioAlberta's 2024 Company of the Year. The award acknowledges a company that has shown significant achievement within the marketplace and Alberta's business community through ...

4,8-9 Patients with EGFRm NSCLC are particularly sensitive to treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) which blocks the cell-signaling pathways that drive the growth of tumor cells.

PHILADELPHIA, PA / ACCESSWIRE /5, 2024 / Prevail Partners LLC ('Prevail Partners') and Prevail InfoWorks Inc. ('Prevail InfoWorks') announce that they have entered into a strategic relationship with ...

Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience ...

Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentationUTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the ...

With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharma’s NXP900 ...

Bicara says the dual approach of its drug blocks survival signaling from EGFR as well as immunosuppressive TGF-beta signaling in the TME. Bicara has been testing its experimental drug in ...